PE20061125A1 - Composicion farmaceutica que comprende acetaminofen, cafeina y opcionalmente aspirina junto a un agente alcalino - Google Patents
Composicion farmaceutica que comprende acetaminofen, cafeina y opcionalmente aspirina junto a un agente alcalinoInfo
- Publication number
- PE20061125A1 PE20061125A1 PE2005001253A PE2005001253A PE20061125A1 PE 20061125 A1 PE20061125 A1 PE 20061125A1 PE 2005001253 A PE2005001253 A PE 2005001253A PE 2005001253 A PE2005001253 A PE 2005001253A PE 20061125 A1 PE20061125 A1 PE 20061125A1
- Authority
- PE
- Peru
- Prior art keywords
- caffeine
- composition
- alkaline agent
- calcium carbonate
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION ANALGESICA/ANTIPIRETICA QUE CONTIENE UNA CANTIDAD EFECTIVA DE ACETAMINOFEN, CAFEINA Y OPCIONALMENTE ASPIRINA. SE REFIERE TAMBIEN A UN METODO QUE COMPRENDE LA INCORPORACION EN LA PRIMERA COMPOSICION DE UNA CANTIDAD ADECUADA DE UN AGENTE ALCALINO SELECCIONADO DE CARBONATO DE CALCIO, MEZCLA DE CARBONATO DE CALCIO E HIDROXIDO DE MAGNESIO, MEZCLA DE CARBONATO DE CALCIO, CARBONATO DE MAGNESIO Y OXIDO DE MAGNESIO Y PRODUCIR UNA SEGUNDA COMPOSICION BIOEQUIVALENTE A LA PRIMERA CON EL OBJETIVO DE ACELERAR LA ACTIVIDAD ANALGESICA/ANTIPIRETICA DE DICHA COMPOSICION. LA COMPOSICION PUEDE CONTENER 250mg DE ASPIRINA, 250 mg DE ACETAMINOFEN, 65mg DE CAFEINA, 43mg DE CARBONATO DE CALCIO, 75mg DE HIDROXIDO DE MAGNESIO, 5mg DE ACIDO CITRICO Y 5mg DE FOSFATO DE SODIO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62281204P | 2004-10-28 | 2004-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20061125A1 true PE20061125A1 (es) | 2006-11-08 |
Family
ID=35744599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005001253A PE20061125A1 (es) | 2004-10-28 | 2005-10-26 | Composicion farmaceutica que comprende acetaminofen, cafeina y opcionalmente aspirina junto a un agente alcalino |
Country Status (17)
Country | Link |
---|---|
US (1) | US20070298096A1 (es) |
EP (1) | EP1807068B1 (es) |
JP (1) | JP2008518914A (es) |
CN (1) | CN101048155A (es) |
AR (1) | AR051145A1 (es) |
AT (1) | ATE460930T1 (es) |
AU (1) | AU2005302618B2 (es) |
BR (1) | BRPI0520000A2 (es) |
CA (1) | CA2583517C (es) |
DE (1) | DE602005020048D1 (es) |
MX (1) | MX2007005121A (es) |
NO (1) | NO20072255L (es) |
PE (1) | PE20061125A1 (es) |
PL (1) | PL1807068T3 (es) |
PT (1) | PT1807068E (es) |
RU (1) | RU2398571C2 (es) |
WO (1) | WO2006049978A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0607085D0 (en) | 2006-04-07 | 2006-05-17 | Smithkline Beecham Corp | Novel compositions |
CN100417385C (zh) * | 2006-09-26 | 2008-09-10 | 林星 | 一种用于治疗外伤的外用制剂 |
GB0707489D0 (en) * | 2007-04-18 | 2007-05-23 | Renaissance Pharma | Compounds |
CN101596163B (zh) * | 2008-06-06 | 2012-06-27 | 康美保宁(四川)制药有限公司 | 阿咖酚微丸制剂及其制备方法 |
GB0813929D0 (en) * | 2008-07-30 | 2008-09-03 | Glaxo Group Ltd | Novel method |
CN102861040B (zh) * | 2012-08-02 | 2014-04-23 | 广东环球制药有限公司 | 含有阿司匹林、对乙酰氨基酚和咖啡因的药物组合物及其制备方法 |
CN102949401A (zh) * | 2012-09-06 | 2013-03-06 | 广东九明制药有限公司 | 对乙酰氨基酚、乙酰水杨酸和咖啡因组合物及其制备工艺 |
US10124005B1 (en) * | 2017-12-15 | 2018-11-13 | Lisa Josette Myslinski | Multisymptom migraine combination medication |
CN110711197B (zh) * | 2018-07-12 | 2023-11-24 | 北京恒润泰生医药科技有限公司 | 阿司匹林和对乙酰氨基酚的分子复合物加咖啡因,其制备,活性及应用 |
CN108853124A (zh) * | 2018-08-15 | 2018-11-23 | 康美保宁(四川)制药有限公司 | 一种阿咖酚制剂及其制剂方法 |
GB202007670D0 (en) * | 2020-05-22 | 2020-07-08 | Glaxosmithkline Consumer Healthcare Holdings Us Llc | Pharmaceutical composition |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4294819A (en) * | 1980-08-18 | 1981-10-13 | Bristol-Myers Company | Alkaline analgesic capsule |
CA1182049A (en) * | 1981-07-13 | 1985-02-05 | Francis J. Sterbenz | Apap antacid composition |
US5296241A (en) * | 1991-04-03 | 1994-03-22 | Brimberg Barnett J | Therapeutic composition and method of using same for treatment of hangover |
JP3122748B2 (ja) * | 1991-11-29 | 2001-01-09 | ライオン株式会社 | イブプロフェン含有解熱鎮痛剤 |
JP3172749B2 (ja) * | 1992-02-17 | 2001-06-04 | ライオン株式会社 | イブプロフェン含有製剤 |
JPH06227995A (ja) * | 1993-02-03 | 1994-08-16 | Takeda Chem Ind Ltd | 安定化された固型製剤 |
JPH07206689A (ja) * | 1994-01-21 | 1995-08-08 | Barnett Lab Ltd | 治療組成物および宿酔の治療のためのこの組成物の使用法 |
DE19502789A1 (de) * | 1995-01-28 | 1996-08-01 | Dirk Krischenowski | Arzneimittel |
GB9704524D0 (en) * | 1997-03-05 | 1997-04-23 | Smithkline Beecham Plc | Composition |
US5972916A (en) * | 1997-07-14 | 1999-10-26 | Bristol-Myers Squibb Company | Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine |
JP2002012557A (ja) * | 2000-06-28 | 2002-01-15 | Lion Corp | 内服薬組成物 |
JP4365107B2 (ja) * | 2001-05-25 | 2009-11-18 | エスエス製薬株式会社 | 医薬組成物 |
JP4553552B2 (ja) * | 2003-01-08 | 2010-09-29 | 日東薬品工業株式会社 | 生体リズム応用キット |
-
2005
- 2005-10-26 RU RU2007119641/15A patent/RU2398571C2/ru not_active IP Right Cessation
- 2005-10-26 MX MX2007005121A patent/MX2007005121A/es active IP Right Grant
- 2005-10-26 AR ARP050104491A patent/AR051145A1/es not_active Application Discontinuation
- 2005-10-26 PL PL05821186T patent/PL1807068T3/pl unknown
- 2005-10-26 AT AT05821186T patent/ATE460930T1/de not_active IP Right Cessation
- 2005-10-26 AU AU2005302618A patent/AU2005302618B2/en active Active
- 2005-10-26 US US11/666,528 patent/US20070298096A1/en not_active Abandoned
- 2005-10-26 DE DE602005020048T patent/DE602005020048D1/de active Active
- 2005-10-26 PT PT05821186T patent/PT1807068E/pt unknown
- 2005-10-26 CA CA2583517A patent/CA2583517C/en not_active Expired - Fee Related
- 2005-10-26 CN CNA2005800370243A patent/CN101048155A/zh active Pending
- 2005-10-26 PE PE2005001253A patent/PE20061125A1/es not_active Application Discontinuation
- 2005-10-26 WO PCT/US2005/038507 patent/WO2006049978A1/en active Application Filing
- 2005-10-26 EP EP05821186A patent/EP1807068B1/en active Active
- 2005-10-26 BR BRPI0520000-8A patent/BRPI0520000A2/pt not_active IP Right Cessation
- 2005-10-26 JP JP2007539060A patent/JP2008518914A/ja active Pending
-
2007
- 2007-05-02 NO NO20072255A patent/NO20072255L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ATE460930T1 (de) | 2010-04-15 |
WO2006049978A1 (en) | 2006-05-11 |
CA2583517A1 (en) | 2006-05-11 |
BRPI0520000A2 (pt) | 2009-04-07 |
MX2007005121A (es) | 2007-06-22 |
CN101048155A (zh) | 2007-10-03 |
US20070298096A1 (en) | 2007-12-27 |
RU2007119641A (ru) | 2008-12-10 |
CA2583517C (en) | 2013-06-04 |
AR051145A1 (es) | 2006-12-20 |
EP1807068B1 (en) | 2010-03-17 |
EP1807068A1 (en) | 2007-07-18 |
AU2005302618A1 (en) | 2006-05-11 |
PT1807068E (pt) | 2010-04-19 |
JP2008518914A (ja) | 2008-06-05 |
NO20072255L (no) | 2007-07-18 |
AU2005302618B2 (en) | 2009-10-22 |
DE602005020048D1 (de) | 2010-04-29 |
PL1807068T3 (pl) | 2010-08-31 |
RU2398571C2 (ru) | 2010-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2582779T3 (es) | Forma de dosificación oral de acetaminofeno/tramadol de liberación prolongada | |
BRPI0709847B8 (pt) | composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio | |
PE20061125A1 (es) | Composicion farmaceutica que comprende acetaminofen, cafeina y opcionalmente aspirina junto a un agente alcalino | |
GT200200105A (es) | Nueva composicion farmaceutica | |
AR018829A1 (es) | Formulaciones farmaceuticas solidas de rapida desintegracion, administrables via oral y procedimiento para prepararlos | |
CR9792A (es) | Composiciones que contienen piperacilina y tazobactam utiles para inyecciones (divisional de exp. 8035) | |
IS7142A (is) | Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi | |
BRPI0415121A (pt) | material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida | |
DE60319355D1 (de) | Kaubare weichkapsel | |
ES2168013T3 (es) | Formulaciones solidas y de rapida desintegracion de cetirizina. | |
MY151470A (en) | Controlled release solid preparation | |
PL1608346T3 (pl) | Kompozycje dostarczające lek zawierające estry alfa-hydroksykwasów i sposób ich zastosowania | |
ES2547644T3 (es) | Procedimiento de molienda | |
UY32624A (es) | Procedimiento y composición para mejorar la absorción de agentes terapéuticos | |
CO5540295A2 (es) | Comprimido para tragar que comprende paracetamol | |
ES2072647T3 (es) | Composiciones que contienen sales de ranitidina/carboxilato de bismuto. | |
KR890006236A (ko) | 피페리디노 알칸올-충혈제거제 조합을 위한 약제학적 조성물 | |
DE50105710D1 (de) | Pharmazeutische, ramipril enthaltende brauseformulierung | |
WO2003028624A3 (en) | Levothyroxine compositions and methods | |
EA200701228A1 (ru) | Стабильные композиции фенофибрата с эфирами жирных кислот | |
AR062486A1 (es) | Formulaciones nuevas para la liberacion controlada de principios activos agroquimicos | |
CR9424A (es) | Ibuprofeno solubilizado | |
WO2004014318A3 (en) | Levothyroxine compositions and methods | |
CR8973A (es) | Composicion farmaceutica en forma de una forma de dosificacion solida soluble en agua | |
WO2003013441A3 (en) | Levothyroxine compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |